|本期目录/Table of Contents|

[1]阎 晗,于明航 综 述,尹 洁,等.组蛋白H3K4甲基转移酶KMT2D研究进展[J].天津医科大学学报,2018,24(06):562-565.
点击复制

组蛋白H3K4甲基转移酶KMT2D研究进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
24卷
期数:
2018年06期
页码:
562-565
栏目:
综述
出版日期:
2018-11-20

文章信息/Info

Title:
-
作者:
阎 晗; 于明航 综 述 ; 尹 洁; 王 玺 审 校
（天津医科大学细胞生物学系，天津 300070）
Author(s):
-
关键词:
KMT2D; H3K4甲基转移酶; H3K4甲基化; 增强子; 表观遗传调控
Keywords:
-
分类号:
Q7
DOI:
-
文献标志码:
A
摘要:
组蛋白-赖氨酸 N-甲基转移酶2D（KMT2D），属于哺乳动物H3K4甲基转移酶家族成员，在成人组织中广泛表达，对于早期胚胎发育有重要作用。C-末端的SET区域负责组蛋白H3K4甲基化，维持KMT2D蛋白的稳定性。KMT2D与WRAD、NCOA6、PTIP、PA1和H3K27去甲基化酶 UTX组成复合物，在其中起到支架蛋白的作用，维持UTX的稳定性。KMT2D主要催化哺乳动物H3K4单甲基化，与转录因子共同作用于增强子区域，从而调控基因表达。KMT2D在调节细胞发育、分化、新陈代谢和肿瘤抑制方面具有重要作用，其突变导致多种疾病发生。进一步研究KMT2D有助于揭示其异常所引发多种疾病的病因，并且对开发临床药物提供有力的帮助。
Abstract:
-

参考文献/References:


[1] Calo E，Wysocka J. Modification of enhancer chromatin: what，how，and why? [J]. Mol Cell，2013，49（5）: 825
[2] Roguev A，Schaft D，Shevchenko A，et al. The saccharomyces cerevisiae set1 complex includes an Ash2 homologue and methylates histone 3 lysine 4 [J]. EMBO J，2001，20（24）: 7137
[3] Ruthenburg A J，Allis C D，Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark [J]. Mol Cell，2007，25（1）: 15
[4] Dhar S S，Lee S H，Kan P Y，et al. Trans-tail regulation of MLL4-catalyzed H3K4 methylation by H4R3 symmetric dimethylation is mediated by a tandem PHD of MLL4 [J]. Gene Dev，2012，26（24）: 2749
[5] Dorighi K M，Swigut T，Henriques T，et al. Mll3 and Mll4 Facilitate Enhancer RNA Synthesis and Transcription from Promoters Independently of H3K4 Monomethylation [J]. Mol Cell，2017，66（4）:568
[6] Jang Y，Wang C，Zhuanng L，et al. H3K4 Methyltransferase Activity Is Required for MLL4 Protein Stability[J]. J Mol Biol，2017， 429（13）: 2046
[7] Rao R C，Dou Y. Hijacked in cancer: the KMT2 （MLL） family of methyltransferases [J]. Nat Rev Cancer，2015，15（6）: 334
[8] Cho Y W，Hong T，Hong S，et al. PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex [J]. J Biol Chem，2007，282（28）: 20395
[9] Lee M G，Villa R，Trojer P，et al. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination[J]. Science，2007， 318（5849）: 447
[10] Erns T P，Vakoc C R. WRAD: enabler of the SET1-family of H3K4 methyltransferases [J]. Brief Funct Genomics，2012，11（3）: 217
[11] Cho Y W，Hong S，Ge K. Affinity purification of MLL3/MLL4 histone H3K4 methyltransferase complex[J]. Methods Mol Biol，2012， 809: 465
[12] Bulger M，Groudine M. Functional and mechanistic diversity of distal transcription enhancers [J]. Cell，2011，144（3）: 327
[13] Lee J E，Wang C，Xu S，et al. H3K4 mono-and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation [J]. Elife，2013，2: e01503
[14] Lai B，Lee J E，Jang Y，et al. MLL3/MLL4 are required for CBP/p300 binding on enhancers and super-enhancer formation in brown adipogenesis [J]. Nucleic Acids Res，2017，45（11）: 6388
[15] Wang C，Lee J E，Lai B，et al. Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition[J]. P Natl Acad Sci USA，2016，113（42）: 11871
[16] Faralli H，Wang C，Nakka K，et al. UTX demethylase activity is required for satellite cell-mediated muscle regeneration[J]. J Clin Invest，2016，126（4）: 1555
[17] Ang S Y，Uebersohm A，Spencer C I，et al. KMT2D regulates specific programs in heart development via histone H3 lysine 4 di-methylation [J]. Development，2016，143（5）: 810
[18] Ortega-molina A，Boss I W，Canfla A，et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development[J]. Nat Med，2015，21（10）: 1199
[19] Munehira Y，Yang Z，Gozani O. Systematic analysis of known and candidate lysine demethylases in the regulation of myoblast differentiation [J]. J Mol Biol，2017，429（13）: 2055
[20] Kim D H，Rhee J C，Yeo S，et al. Crucial roles of mixed-lineage leukemia 3 and 4 as epigenetic switches of the hepatic circadian clock controlling bile acid homeostasis in mice[J]. Hepatology，2015， 61（3）: 1012
[21] Kim D H，Kim J，Kwon J S，et al. Critical roles of the histone methyltransferase MLL4/KMT2D in murine hepatic steatosis directed by ABL1 and PPARgamma2[J]. Cell Rep，2016，17（6）: 1671v
[22] Lee J，Kim D H，Lee S，et al. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4 [J]. P Natl Acad Sci USA，2009，106（21）: 8513b
[23] Chen C，Liu Y，Rappaport A R，et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia[J]. Cancer Cell，2014， 25（5）: 652
[24] Zhang J，Dominguez-sola D，Hussein S，et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis [J]. Nat Med，2015，21（10）: 1190
[25] Guo C，Chen L H，Huang Y，et al. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation[J]. Oncotarget，2013，4（11）: 2144
[26] Kim J H，Sharma A，Dhar S S，et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells[J]. Cancer Res，2014，74（6）: 1705
[27] Toska E，Osmabeyoglu H U，Castel P，et al. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D [J]. Science，2017，355（6331）: 1324
[28] BogershauSsen N，Wollnik B. Unmasking Kabuki syndrome [J]. Clin Genet，2013，83（3）: 201
[29] Zaidl S，Choi M，Wakimoto H，et al. De novo mutations in histone-modifying genes in congenital heart disease[J]. Nature，2013，498（7453）: 220
[30] Lawrence M S，Stojanov P，Mermel C H，et al. Discovery and saturation analysis of cancer genes across 21 tumour types[J]. Nature，2014，505（7484）: 495
[31] Jones D T，Jager N，Kool M，et al. Dissecting the genomic complexity underlying medulloblastoma [J]. Nature，2012，488（7409）: 100
[32] Juhlin C C，Stenman A，Haglund F，et al. Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene[J]. Genes Chromosomes Cancer，2015，54（9）: 542
[33] Morin R D，Mendez-Lago M，Mungall A J，et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma [J]. Nature，2011，476（7360）: 298
[34] Lohr J G，Stojanov P，Lawrence M S，et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma （DLBCL） by whole-exome sequencing[J]. P Natl Acad Sci USA，2012，109（10）: 3879
[35] Gao Y B，Chen Z L，Li J G，et al. Genetic landscape of esophageal squamous cell carcinoma [J]. Nat Genet，2014，46（10）: 1097
[36] Sausen M，Phallen J，Adleff V，et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients [J]. Nat Commun，2015，6: 7686
[37] Grasso C S，Wu Y M，Robinson D R，et al. The mutational landscape of lethal castration-resistant prostate cancer[J]. Nature，2012，487（7406）: 239

相似文献/References:

备注/Memo

备注/Memo:
基金项目 国家重点基础研究发展计划基金资助项目（2014CB910100）；国家自然科学基金资助项目（31600705）；国家自然科学基金资助项目（31600693）
作者简介 阎晗（1989-），女，助理实验师，硕士，研究方向：肿瘤免疫；通信作者：王玺，E-mail：wangxi@tmu.edu.cn。
更新日期/Last Update: 2018-11-30